EP1278769A2 - Antigenes de la tuberculose et procedes de leur utilisation - Google Patents

Antigenes de la tuberculose et procedes de leur utilisation

Info

Publication number
EP1278769A2
EP1278769A2 EP01923542A EP01923542A EP1278769A2 EP 1278769 A2 EP1278769 A2 EP 1278769A2 EP 01923542 A EP01923542 A EP 01923542A EP 01923542 A EP01923542 A EP 01923542A EP 1278769 A2 EP1278769 A2 EP 1278769A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
acid sequence
nucleic acid
amino acid
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01923542A
Other languages
German (de)
English (en)
Inventor
Else Marie Agger
Peter Andersen
Li Mei Meng Okkels
Karin Weldingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of EP1278769A2 publication Critical patent/EP1278769A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention discloses new immunogenic polypeptides and new immunogenic compositions based on polypeptides derived from the short time culture filtrate of M. tuberculosis.
  • M. tuberculosis Human tuberculosis caused by Mycobacterium tuberculosis (M. tuberculosis) is a severe global health problem, responsible for approx. 3 million deaths annually, according to the WHO.
  • BCG The only vaccine presently available for clinical use is BCG, a vaccine whose efficacy re- mains a matter of controversy. BCG generally induces a high level of acquired resistance in animal models of TB, but several human trials in developing countries have failed to demonstrate significant protection. Notably, BCG is not approved by the FDA for use in the United States because BCG vaccination impairs the specificity of the Tuberculin skin test for diagnosis of TB infection.
  • Immunity to M. tuberculosis is characterized by some basic features; specifically sensitized T lymphocytes mediates protection, and the most important mediator molecule seems to be interferon gamma (IFN- ⁇ ).
  • IFN- ⁇ interferon gamma
  • M. tuberculosis holds, as well as secretes, several proteins of potential relevance for the generation of a new TB vaccine.
  • a major effort has been put into the identification of new protective antigens for the development of a novel vaccine against TB.
  • the search for candidate molecules has primarily focused on proteins released from dividing bacteria. Despite the characterization of a large number of such proteins only a few of these have been demonstrated to induce a protective immune re- sponse as subunit vaccines in animal models, most notably ESAT-6 and Ag85B (Brandt et al 2000).
  • M. tuberculosis infection in its earliest stage is important for effective treat- ment of the disease.
  • Current diagnostic assays to determine M. tuberculosis infection are expensive and labour-intensive.
  • the majority of patients exposed to M. tuberculosis receive chest x-rays and attempts are made to culture the bacterium in vitro from sputum samples.
  • X-rays are insensitive as a diagnostic assay and can only identify infections in a very progressed stage.
  • Culturing of M. tuberculosis is also not ideal as a diagnostic tool, since the bacteria grows poorly and slowly outside the body, which can produce false negative test results and take weeks before results are obtained.
  • the standard tuberculin skin test is an inexpensive assay, used in third world countries, however it is far from ideal in detecting infection because it cannot distinguish M. tuberculosis-infected individuals from M. bovis BCG-vaccinated individuals and there- fore cannot be used in areas of the world where patients receive or have received childhood vaccination with bacterial strains related to M. tuberculosis, e.g. a BCG vaccination.
  • M. bovis is an important pathogen that can infect a range of hosts, including cattle and humans. Tuberculosis in cattle is a major cause of economic loss and represents a significant cause of zoonotic infection.
  • a number of strategies have been employed against bovine TB, but the approach has generally been based on government-organized programs by which animals deemed positive to defined screening test are slaughtered. The most common test used in cattle is Delayed- type hypersensitivity with PPD as antigen, but alternative in vitro assays are also developed.
  • the invention is related to preventing, treating and detecting infections caused by species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum) by the use of a polypeptide comprising a M. tuberculosis antigen or an immunogenic portion or other variant thereof, or by the use of a DNA sequence encoding a M. tuberculosis antigen or an immunogenic portion or other variant thereof.
  • species of the tuberculosis complex M. tuberculosis, M. bovis, M. africanum
  • the present invention discloses a substantially pure polypeptide, which comprises an amino acid sequence selected from (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878,
  • an immunogenic portion e.g. a T-cell epitope, of any one of the sequences in (a); and /or
  • the amino acid sequence analogue has at least 80%, more preferred at least 90% and most preferred at least 95% sequence identity to any one of the sequences in (a) or (b).
  • the invention further discloses a fusion polypeptide, which comprises an amino acid sequence selected from (a) Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1
  • an immunogenic portion e.g. a T-cell epitope, of any one of the sequences in (a); and /or (c) an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic; and at least one fusion partner.
  • the fusion partner comprises a polypeptide fragment selected from (a) a polypeptide fragment derived from a virulent mycobacterium, such as ESAT-6,
  • the invention further relates to a polypeptide, which comprises an amino acid sequence selected from
  • an immunogenic portion e.g. a T-cell epitope, of any one of the sequences in (a); and /or
  • an amino acid sequence analogue having at least 70% sequence identity to any one of the sequences in (a) or (b) and at the same time being immunogenic; which is lipidated so as to allow a self-adjuvating effect of the polypeptide.
  • polypeptide which comprises an amino acid sequence selected from
  • an immunogenic portion e.g. a T-cell epitope, of any one of the sequences in (a); and /or
  • the invention relates to the use of a polypeptide as defined above for the preparation of a pharmaceutical composition for diagnosis, e.g. for diagnosis of tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Myco- bacterium africanum or Mycobacterium bovis, and the use of a polypeptide as defined above for the preparation of a pharmaceutical composition, e.g. for the vaccination against infection caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis.
  • the invention relates to an immunogenic composition
  • an immunogenic composition comprising a polypeptide as defined above, preferably in the form of a vaccine or in the form of a skin test reagent.
  • the invention relates to a nucleic acid fragment in isolated form which
  • (a) comprises a nucleic acid sequence which encodes a polypeptide as defined above, or comprises a nucleic acid sequence complementary thereto;
  • (b) has a length of at least 10 nucleotides and hybridizes readily under stringent hybridization conditions with a nucleotide sequence selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195, Rv1386, Rv3477, Rv3878, Rv3879c or MT3106.1 nucleotide sequences or a sequence complementary thereto, or with a nucleotide sequence selected from a sequence in (a)
  • the nucleic acid fragment is preferably a DNA fragment.
  • the fragment can be used as a pharmaceutical.
  • the invention relates to a vaccine comprising a nucleic acid fragment according to the invention, optionally inserted in a vector, the vaccine effecting in vivo expression of antigen by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, in an animal, including a human being.
  • virulent mycobacteria e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis
  • the invention relates to the use of a nucleic acid fragment according to the invention for the preparation of a composition for the diagnosis of tuberculosis caused by virulent mycobacteria, e. g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, and the use of a nucleic acid fragment according to the invention for the preparation of a pharmaceutical composition for the vaccination against tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis.
  • the invention relates to a vaccine for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising as the effective component a non-pathogenic microorganism, wherein at least one copy of a DNA fragment comprising a DNA sequence encoding a polypeptide as defined above has been incorporated into the microorganism (e.g. placed on a plasmid or in the genome) in a manner allowing the microorganism to express and optionally secrete the polypeptide.
  • virulent mycobacteria e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis
  • the invention relates to a replicable expression vector, which comprises a nucleic acid fragment according to the invention, and a transformed cell har- bouring at least one such vector.
  • the invention relates to a method for producing a polypeptide as defined above, comprising
  • the invention also relates to a method of diagnosing tuberculosis caused by virulent my- cobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Myco- bacterium bovis, in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide as defined above or an immunogenic composition as defined above, a positive skin response at the location of injection being indicative of the animal having tuberculosis, and a negative skin response at the location of injection being indicative of the animal not having tuberculosis.
  • virulent my- cobacteria e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Myco- bacterium bovis
  • the invention in another embodiment, relates to a method for immunizing an animal, including a human being, against tuberculosis caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis, comprising administering to the animal the polypeptide as defined above, the immunogenic composition according to the invention, or the vaccine according to the invention.
  • virulent mycobacteria e.g. by Mycobacterium tuberculosis, Mycobacterium africanum or Mycobacterium bovis
  • Another embodiment of the invention relates to a monoclonal or polyclonal antibody, which is specifically reacting with a polypeptide as defined above in an immuno assay, or a specific binding fragment of said antibody.
  • said antibody is for use as a diagnostic reagent, e.g. for detection of mycobacterial antigens in sputum, urine or other body fluids of an infected animal, including a human being.
  • the invention relates to a pharmaceutical composition which comprises an immunologically responsive amount of at least one member selected from the group consisting of: (a) a polypeptide selected from Rv0284, Rv0285, Rv0455c, Rv0569, Rv1195,
  • a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;
  • nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to (d) or (e); and (g) a non-pathogenic micro-organism which has incorporated (e.g. placed on a plasmid or in the genome) therein a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
  • a fusion polypeptide comprising at least one polypeptide or amino acid sequence according to (a) or (b) and at least one fusion partner;
  • nucleic acid sequence which has a length of at least 10 nucleotides and which hybridizes under stringent conditions with a nucleic acid sequence according to
  • a non-pathogenic micro-organism which has incorporated therein (e.g. placed on a plasmid or in the genome) a nucleic acid sequence according to (d), (e) or (f) in a manner to permit expression of a polypeptide encoded thereby.
  • the vaccine, immunogenic composition and pharmaceutical composition according to the invention can be used prophylactically in a subject not infected with a virulent mycobacterium; or therapeutically in a subject already infected with a virulent mycobacterium.
  • the invention also relates to a method for diagnosing previous or ongoing infection with a virulent mycobacterium, said method comprising
  • a sample e.g. a blood sample
  • a composition comprising an antibody according to the invention, a nucleic acid fragment according to the invention and/or a polypeptide as defined above
  • a sample e.g. a blood sample comprising mononuclear cells (e.g. T- lymphocytes)
  • a composition comprising one or more polypeptides as defined above in order to detect a positive reaction, e.g. proliferation of the cells or release of cytokines such as IFN- ⁇ .
  • the invention relates to a method of diagnosing Mycobacterium tuberculosis infection in a subject comprising:
  • polypeptide in the present invention should have its usual meaning. That is an amino acid chain of any length, including a full-length protein, oligopeptides, short peptides and fragments thereof, wherein the amino acid residues are linked by covalent peptide bonds.
  • the polypeptide may be chemically modified by being glycosylated, by being lipidated (e.g. by chemical lipidation with palmitoyloxy succinimide as described by Mowat et al. 1991 or with dodecanoyl chloride as described by Lustig et al. 1976), by comprising prosthetic groups, or by containing additional amino acids such as e.g. a his-tag or a signal peptide.
  • Each polypeptide may thus be characterised by specific amino acids and be encoded by specific nucleic acid sequences. It will be understood that such sequences include analogues and variants produced by recombinant or synthetic methods wherein such polypeptide sequences have been modified by substitution, insertion, addition or deletion of one or more amino acid residues in the recombinant polypeptide and still be immunogenic in any of the biological assays described herein. Substitutions are preferably "conservative". These are defined according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other. The amino acids in the third column are indicated in one-letter code.
  • a preferred polypeptide within the present invention is an immunogenic antigen from M. tuberculosis.
  • antigen can for example be derived from M. tuberculosis and/or M. tuberculosis culture filtrate.
  • a polypeptide comprising an immunogenic portion of one of the above antigens may consist entirely of the immunogenic portion, or may contain additional sequences.
  • the additional sequences may be derived from the native M. tuberculosis antigen or be heterologous and such sequences may, but need not, be immunogenic.
  • Each polypeptide is encoded by a specific nucleic acid sequence. It will be understood that such sequences include analogues and variants hereof wherein such nucleic acid sequences have been modified by substitution, insertion, addition or deletion of one or more nucleic acid. Substitutions are preferably silent substitutions in the codon usage which will not lead to any change in the amino acid sequence, but may be introduced to enhance the expression of the protein.
  • substantially pure polypeptide fragment means a polypeptide preparation which contains at most 5% by weight of other polypeptide material with which it is natively associated (lower percentages of other polypeptide material are preferred, e.g. at most 4%, at most 3%, at most 2%, at most 1%, and at most 1 %). It is preferred that the substantially pure polypeptide is at least 96% pure, i.e. that the polypeptide constitutes at least 96% by weight of total polypeptide material present in the preparation, and higher percentages are preferred, such as at least 97%, at least 98%, at least 99%, at least 99,25%, at least 99,5%, and at least 99,75%.
  • the polypeptide fragment is in "essentially pure form", i.e. that the polypeptide fragment is essentially free of any other antigen with which it is natively associated, i.e. free of any other antigen from bacteria belonging to the tuberculosis complex or a virulent mycobacterium.
  • This can be accomplished by preparing the polypeptide fragment by means of recombinant methods in a non-mycobacterial host cell as will be described in detail below, or by synthesizing the polypeptide fragment by the well-known methods of solid or liquid phase peptide synthesis, e.g. by the method described by Merrifield or variations thereof.
  • virulent mycobacterium is understood a bacterium capable of causing the tuberculosis disease in an animal or in a human being.
  • virulent mycobacteria are M. tuberculosis, M. africanum, and M. bovis.
  • relevant animals are cattle, possums, badgers and kangaroos.
  • a TB patient an individual with culture or microscopically proven infection with virulent mycobacteria, and/or an individual clinically diagnosed with TB and who is responsive to anti-TB chemotherapy. Culture, microscopy and clinical diagnosis of TB are well known by any person skilled in the art.
  • PPD-positive individual an individual with a positive Mantoux test or an individual where PPD induces a positive in vitro recall response determined by release of IFN- ⁇ .
  • DTH delayed type hypersensitivity reaction
  • IFN- ⁇ interferon-gamma.
  • the measurement of IFN- ⁇ is used as an indication of an immunological response.
  • nucleic acid fragment and “nucleic acid sequence” are understood any nucleic acid molecule including DNA, RNA, LNA (locked nucleic acids), PNA, RNA, dsRNA and RNA-DNA-hybrids. Also included are nucleic acid molecules comprising non-naturally occurring nucleosides. The term includes nucleic acid molecules of any length, e.g. from 10 to 10000 nucleotides, depending on the use. When the nucleic acid molecule is for use as a pharmaceutical, e.g.
  • a molecule encoding at least one epitope is preferably used, having a length from about 18 to about 1000 nucleotides, the molecule being op- tionally inserted into a vector.
  • a molecule having a length of 10-100 is preferably used.
  • molecule lengths can be used, for instance a molecule having at least 12, 15, 21 , 24, 27, 30, 33, 36, 39, 42, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 or 1000 nucleotides (or nucleotide derivatives), or a molecule having at most 10000, 5000, 4000, 3000, 2000, 1000, 700, 500, 400, 300, 200, 100, 50, 40, 30 or 20 nucleotides (or nucleotide derivatives). It should be understood that these numbers can be freely combined to produce ranges.
  • stringent when used in conjunction with hybridization conditions is as defined in the art, i.e. the hybridization is performed at a temperature not more than 15-20°C under the melting point Tm, cf. Sambrook et al, 1989, pages 11.45-11.49.
  • the conditions are "highly stringent", i.e. 5-10°C under the melting point Tm.
  • sequence identity indicates a quantitative measure of the degree of homology between two amino acid sequences of equal length or between two nucleotide sequences of equal length. If the two sequences to be compared are not of equal length, they must be aligned to best possible fit possible with the insertion of gaps or alternatively truncation at the ends of the protein sequences.
  • sequence identity can be calculated as W Tti V 00 _ wherein N dlf is the total number of non-identical residues in the two sequences when aligned and wherein N ref is the number of residues in one of the sequences.
  • Sequence identity can alternatively be calculated by the BLAST program e.g. the BLASTP program (Pearson W. R. and D. J. Lipman (1988))(www.ncbi. nlm.nih.gov/cgi-bin/BLAST).
  • alignment is performed with the sequence alignment method ClustalW with default parameters as described by Thompson J., e al 1994, available at http://www2.ebi.ac.uk/clustalw/.
  • a preferred minimum percentage of sequence identity is at least 80%, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, and at least 99.5%.
  • the polypeptide comprises an immunogenic portion of the polypeptide, such as an epitope for a B-cell or T-cell.
  • the immunogenic portion of a polypeptide is a part of the polypeptide, which elicits an immune response in an animal or a human being, and/or in a biological sample determined by any of the biological assays described herein.
  • the immunogenic portion of a polypeptide may be a T-cell epitope or a B-cell epitope.
  • Immunogenic portions can be related to one or a few relatively small parts of the polypeptide, they can be scattered throughout the polypeptide sequence or be situated in specific parts of the polypeptide. For a few polypeptides epitopes have even been demonstrated to be scattered throughout the polypeptide covering the full sequence (Ravn et al 1999).
  • T-cell epitopes are linear, deletion mutants of the polypeptide will, if constructed systematically, reveal what regions of the polypeptide are essential in immune recognition, e.g. by subjecting these deletion mutants e.g. to the IFN- ⁇ assay described herein.
  • Another method utilises overlapping oligopeptides for the detection of MHC class II epitopes, preferably synthetic, having a length of e.g. 20 amino acid residues derived from the polypeptide. These peptides can be tested in biological assays (e.g.
  • the IFN- ⁇ assay as described herein will give a positive response (and thereby be immunogenic) as evidence for the presence of a T cell epitope in the peptide.
  • MHC class I epitopes it is possible to predict peptides that will bind (Stryhn et al. 1996) and hereafter produce these peptides synthetic and test them in relevant biological assays e.g. the IFN- ⁇ assay as described herein.
  • the peptides preferably having a length of e.g. 8 to 11 amino acid residues derived from the polypeptide.
  • B-cell epitopes can be determined by analysing the B cell recognition to overlapping peptides covering the polypeptide of interest as e.g. described in Harboe et al 1998.
  • the polypeptide fragment of the invention has a length of at least 7 amino acid residues, such as at least 8, at least 9, at least 10, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, and at least 30 amino acid residues.
  • the polypeptide fragment has a length of at most 50 amino acid residues, such as at most 40, 35, 30, 25, and 20 amino acid residues. It should be understood that these numbers can be freely combined to produce ranges.
  • the peptides having a length of between 10 and 20 amino acid residues will prove to be most efficient as MHC class II epitopes and therefore especially preferred lengths of the polypeptide fragment used in the inventive method are 18, such as 15, 14, 13, 12 and even 11 amino acid residues. It is expected that the peptides having a length of between 7 and 12 amino acid residues will prove to be most efficient as MHC class I epitopes and therefore especially preferred lengths of the polypeptide fragment used in the inventive method are 11 , such as 10, 9, 8 and even 7 amino acid residues.
  • Immunogenic portions of polypeptides may be recognised by a broad part (high frequency) or by a minor part (low frequency) of the genetically heterogenic human population.
  • some immunogenic portions induce high immunological responses (dominant), whereas others induce lower, but still significant, responses (subdominant).
  • High frequencyxlow frequency can be related to the immunogenic portion binding to widely distributed MHC molecules (HLA type) or even by multiple MHC molecules (Kilgus et al. 1991 , Sinigaglia et al 1988 ).
  • the subdominat epitopes are however as relevant as are the dominat epitopes since it has been show (Olsen et al 2000) that such epitopes can induce protection regardless of being subdominant.
  • polypeptides of the invention are their capability to induce an im- munological response as illustrated in the examples. It is understood that a variant of a polypeptide of the invention produced by substitution, insertion, addition or deletion is also immunogenic determined by any of the assays described herein.
  • An immune individual is defined as a person or an animal, which has cleared or controlled an infection with virulent mycobacteria or has received a vaccination with M. bovis BCG.
  • An immunogenic polypeptide is defined as a polypeptide that induces an immune response in a biological sample or an individual currently or previously infected with a virulent mycobacterium. The immune response may be monitored by one of the following methods:
  • An in vitro cellular response is determined by release of a relevant cytokine such as IFN- ⁇ , from lymphocytes withdrawn from an animal or human being currently or previously infected with virulent mycobacteria, or by detection of proliferation of these T cells.
  • the induction being performed by the addition of the polypeptide or the immunogenic portion to a suspension comprising from 1x10 5 cells to 3x10 5 cells per well.
  • the cells being isolated from either the blood, the spleen, the liver or the lung and the addition of the polypeptide or the immunogenic portion resulting in a concentration of not more than 20 ⁇ g per ml suspension and the stimulation being performed from two to five days.
  • the cells are pulsed with radioactive labeled Thymidine and after 16-22 hours of incubation detecting the proliferation by liquid scintillation counting.
  • a positive response being a response more than background plus two standard derivations.
  • the release of IFN- ⁇ can be determined by the ELISA method, which is well known to a person skilled in the art.
  • a positive response being a response more than background plus two standard derivations.
  • Other cytokines than IFN- ⁇ could be relevant when monitoring the immunological response to the polypeptide, such as IL-12, TNF- ⁇ , IL-4, IL-5, IL-10, IL-6, TGF- ⁇ .
  • Another and more sensitive method for determining the presence of a cytokine e.g.
  • IFN- ⁇ is the ELISPOT method where the cells isolated from either the blood, the spleen, the liver or the lung are diluted to a concentration of preferable of 1 to 4 x 10 6 cells /ml and incubated for 18-22 hrs in the presence of of the polypeptide or the immunogenic portion resulting in a concentration of not more than 20 ⁇ g per ml.
  • the cell suspensions are hereafter diluted to 1 to 2 x 10 6 / ml and transferred to Maxisorp plates coated with anti-IFN- ⁇ and in- cubated for preferably 4 to 16 hours.
  • the IFN- ⁇ producing cells are determined by the use of labeled secondary anti-IFN- ⁇ antibody and a relevant substrate giving rise to spots, which can be enumerated using a dissection microscope. It is also a possibility to determine the presence of mRNA coding for the relevant cytokine by the use of the PCR technique. Usually one or more cytokines will be measured utilizing for example the PCR, ELISPOT or ELISA. It will be appreciated by a person skilled in the art that a significant increase or decrease in the amount of any of these cytokines induced by a specific polypeptide can be used in evaluation of the immunological activity of the polypeptide.
  • An in vitro cellular response may also be determined by the use of T cell lines derived from an immune individual or an M. tuberculosis infected person where the T cell lines have been driven with either live mycobacteria, extracts from the bacterial cell or culture filtrate for 10 to 20 days with the addition of IL-2.
  • the induction being performed by addition of not more than 20 ⁇ g polypeptide per ml suspension to the T cell lines containing from 1x10 5 cells to 3x10 5 cells per well and incubation being performed from two to six days.
  • the induction of IFN- ⁇ or release of another relevant cytokine is detected by ELISA.
  • the stimulation of T cells can also be monitored by detecting cell proliferation using radioactively labeled Thymidine as described above. For both assays a positive response being a response more than background plus two standard derivations.
  • An in vivo cellular response which may be determined as a positive DTH response after intradermal injection or local application patch of at most 100 ⁇ g of the poly- peptide or the immunogenic portion to an individual who is clinically or subclinically infected with a virulent Mycobacterium, a positive response having a diameter of at least 5 mm 72-96 hours after the injection or application.
  • An in vitro humoral response is determined by a specific antibody response in an immune or infected individual.
  • the presence of antibodies may be determined by an ELISA technique or a Western blot where the polypeptide or the immunogenic portion is absorbed to either a nitrocellulose membrane or a polystyrene surface.
  • the serum is preferably diluted in PBS from 1 :10 to 1 :100 and added to the absorbed polypeptide and the incubation being performed from 1 to 12 hours.
  • labeled secondary antibodies the presence of specific antibodies can be determined by measuring the OD e.g. by ELISA where a positive response is a response of more than background plus two standard derivations or alternatively a visual response in a Western blot.
  • Another relevant parameter is measurement of the protection in animal models induced after vaccination with the polypeptide in an adjuvant or after DNA vaccination.
  • Suitable animal models include primates, guinea pigs or mice, which are challenged with an infection of a virulent Mycobacterium. Readout for induced protection could be decrease of the bacterial load in target organs compared to non-vaccinated animals, prolonged survival times compared to non-vaccinated animals and diminished weight loss compared to non-vaccinated animals.
  • M. tuberculosis antigens and DNA sequences encoding such antigens, may be prepared using any one of a variety of procedures. They may be purified as native proteins from the M. tuberculosis cell or culture filtrate by procedures such as those described above. Immunogenic antigens may also be produced recombinantly using a DNA sequence encoding the antigen, which has been inserted into an expression vector and expressed in an appropriate host. Examples of host cells are coli.
  • polypeptides or immunogenic portion hereof can also be produced synthetically having fewer than about 100 amino acids, and generally fewer than 50 amino acids and may be generated using techniques well known to those ordinarily skilled in the art, such as commercially available solid-phase techniques where amino acids are sequentially added to a growing amino acid chain.
  • Plasmid DNA can then be prepared from overnight cultures of the host strain carrying the plasmid of interest, and purified using e.g. the Qiagen Giga -Plasmid column kit (Qiagen, Santa Clarita, CA, USA) including an endotoxin removal step. It is essential that plasmid DNA used for DNA vaccination is endotoxin free.
  • the immunogenic polypeptides may also be produced as fusion proteins, by which methods superior characteristics of the polypeptide of the invention can be achieved.
  • fusion partners that facilitate export of the polypeptide when produced recombinantly fusion partners that facilitate purification of the polypeptide, and fusion partners which enhance the immunogenicity of the polypeptide fragment of the invention are all interesting possibilities. Therefore, the invention also pertains to a fusion polypeptide comprising at least one polypeptide or immunogenic portion defined above and at least one fusion partner.
  • the fusion partner can, in order to enhance immunogenicity, be an- other polypeptide derived from M.
  • tuberculosis such as of a polypeptide fragment derived from a bacterium belonging to the tuberculosis complex, such as ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), MPB59, , Ag85C, 19kDa lipoprotein, MPT32 and alpha-crystallin, or at least one T-cell epitope of any of the above mentioned antigens ((Skj ⁇ t et al 2000; Danish Patent application PA 2000 00666; Danish Patent application PA 1999 01020; US patent application 09/0505,739; Rosenkrands et al 1998; Nagai et al 1991).
  • the invention also pertains to a fusion polypeptide comprising mutual fusions of two or more of the polypeptides (or immunogenic portions thereof) of the invention.
  • fusion partners which could enhance the immunogenicity of the product, are lym- phokines such as IFN- ⁇ , IL-2 and IL-12.
  • the fusion partner can e.g. be a bacterial fimbrial protein, e.g. the pilus components pilin and papA; protein A; the ZZ-peptide (ZZ-fusions are marketed by Pharmacia in Sweden); the maltose binding protein; gluthatione S-transferase; ⁇ -galactosidase; or poly-histidine. Fusion proteins can be produced recombinantly in a host cell, which could be E. coli, and it is a possibility to induce a linker region between the different fusion partners.
  • polypeptides which are lipidated so that the immu- nogenic polypeptide is presented in a suitable manner to the immune system.
  • This effect is e.g. known from vaccines based on the Borrelia burgdorferi OspA polypeptide as described in e.g. WO 96/40718 A or vaccines based on the Pseudomonas aeruginosa Oprl lipoprotein (Cote-Sierra J 1998).
  • Another possibility is N-terminal fusion of a known signal sequence and an N-terminal cystein to the immunogenic polypeptide. Such a fusion re- suits in lipidation of the immunogenic polypeptide at the N-terminal cystein, when produced in a suitable production host.
  • Another part of the invention pertains to a vaccine composition
  • a vaccine composition comprising a polypeptide (or at least one immunogenic portion thereof) or fusion polypeptide according to the in- vention.
  • a vaccine composition comprises an immunologically and pharmaceutically acceptable carrier, vehicle or adjuvant.
  • An effective vaccine wherein a polypeptide of the invention is recognized by the animal, will in an animal model be able to decrease bacterial load in target organs, prolong sur- vival times and/or diminish weight loss after challenge with a virulent Mycobacterium, compared to non-vaccinated animals.
  • Suitable carriers are selected from the group consisting of a polymer to which the poly- peptide(s) is/are bound by hydrophobic non-covalent interaction, such as a plastic, e.g. polystyrene, or a polymer to which the polypeptide(s) is/are covalently bound, such as a polysaccharide, or a polypeptide, e.g. bovine serum albumin, ovalbumin or keyhole limpet haemocyanin.
  • Suitable vehicles are selected from the group consisting of a diluent and a suspending agent.
  • the adjuvant is preferably selected from the group consisting of di- methyldioctadecylammonium bromide (DDA), Quil A, poly l:C, aluminium hydroxide, Freund's incomplete adjuvant, IFN- ⁇ , IL-2, IL-12, monophosphoryl lipid A (MPL), Tre- holose Dimycolate (TDM), Trehalose Dibehenate and muramyl dipeptide (MDP).
  • DDA di- methyldioctadecylammonium bromide
  • Quil A Quil A
  • poly l:C aluminium hydroxide
  • Freund's incomplete adjuvant IFN- ⁇
  • IL-2 interleukin-12
  • MPL monophosphoryl lipid A
  • TDM Tre- holose Dimycolate
  • Trehalose Dibehenate and muramyl dipeptide
  • agents such as aluminum hydroxide or phosphate (alum), synthetic polymers of sugars (Carbopol), ag- gregation of the protein in the vaccine by heat treatment, aggregation by reactivating with pepsin treated (Fab) antibodies to albumin, mixture with bacterial cells such as C. parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria, emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed.
  • Other possibilities involve the use of immune modulating substances such as cytokines or synthetic IFN- ⁇ inducers such as poly l:C in combination with the above-mentioned adjuvants.
  • a relevant antigen such as an antigen of the present invention can be conjugated to an antibody (or antigen binding antibody fragment) against the Fc ⁇ receptors on mono- cytes/macrophages.
  • the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic.
  • the quantity to be administered depends on the subject to be treated, including, e.g., the capacity of the individual's immune system to mount an immune response, and the degree of protection desired.
  • Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a preferred range from about 0.1 ⁇ g to 1000 ⁇ g, such as in the range from about 1 ⁇ g to 300 ⁇ g, and especially in the range from about 10 ⁇ g to 50 ⁇ g.
  • Suitable regimens for initial administration and booster shots are also variable but are typified by an initial administration followed by subsequent inoculations or other admini- strations.
  • the manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection or the like.
  • the dosage of the vaccine will depend on the route of administration and will vary according to the age of the person to be vaccinated and, to a lesser degree, the size of the person to be vaccinated.
  • the vaccines are conventionally administered parenterally, by injection, for example, ei- ther subcutaneously or intramuscularly.
  • Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations.
  • suppositories traditional binders and carriers may include, for example, polyalkalene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1-2%.
  • Oral for- mulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and advantageously contain 10-95% of active ingredient, preferably 25-70%.
  • vaccines can be administered to prevent an infection with virulent mycobacteria and/or to treat established mycobacterial infection.
  • the vaccine When administered to prevent an infection, the vaccine is given prophylactically, before definitive clinical signs or symptoms of an infection are present.
  • the vaccine according to the invention may comprise several different polypeptides in order to increase the immune response.
  • the vaccine may comprise two or more polypeptides or immunogenic portions, where all of the polypeptides are as defined above, or some but not all of the peptides may be derived from virulent mycobacteria.
  • the polypeptides not necessarily fulfilling the criteria set forth above for polypeptides may either act due to their own immunogenicity or merely act as adjuvants.
  • the vaccine may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.
  • the invention also pertains to a method for immunising an animal, including a human be- ing, against TB caused by virulent mycobacteria, comprising administering to the animal the polypeptide of the invention, or a vaccine composition of the invention as described above, or a living vaccine described above.
  • the invention also pertains to a method for producing an immunologic composition accor- ding to the invention, the method comprising preparing, synthesising or isolating a polypeptide according to the invention, and solubilizing or dispersing the polypeptide in a medium for a vaccine, and optionally adding other M. tuberculosis antigens and/or a carrier, vehicle and/or adjuvant substance.
  • nucleic acid fragments of the invention may be used for effecting in vivo expression of antigens, i.e. the nucleic acid fragments may be used in so-called DNA vaccines as reviewed in Ulmer et al 1993, which is included by reference.
  • the invention also relates to a vaccine comprising a nucleic acid fragment ac- cording to the invention, the vaccine effecting in vivo expression of antigen by an animal, including a human being, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to infections caused by virulent mycobacteria in an animal, including a human being.
  • the efficacy of such a DNA vaccine can possibly be enhanced by administering the gene encoding the expression product together with a DNA fragment encoding a polypeptide which has the capability of modulating an immune response.
  • One possibility for effectively activating a cellular immune response for a vaccine can be achieved by expressing the relevant antigen in a vaccine in a non-pathogenic microorganism or virus.
  • a non-pathogenic microorganism or virus are Mycobacterium bovis BCG, Salmonella and Pseudomona and examples of viruses are Vaccinia Virus and Adenovirus.
  • Another important aspect of the present invention is an improvement of the living BCG vaccine presently available, wherein one or more copies of a DNA sequence encoding one or more polypeptide as defined above has been incorporated into the genome of the micro-organism in a manner allowing the micro-organism to express and secrete the polypeptide.
  • the incorporation of more than one copy of a nucleotide sequence of the invention is contemplated to enhance the immune response
  • Another possibility is to integrate the DNA encoding the polypeptide according to the invention in an attenuated virus such as the vaccinia virus or Adenovirus (Rolph et al 1997).
  • the recombinant vaccinia virus is able to replicate within the cytoplasma of the infected host cell and the polypeptide of interest can therefore induce an immune response, which is envisioned to induce protection against TB.
  • the invention also relates to the use of a polypeptide or nucleic acid of the invention for use as therapeutic vaccines as have been described in the literature exemplified by D. Lowry (Lowry et al 1999).
  • Antigens with therapeutic properties may be identified based on their ability to diminish the severity of M. tuberculosis infection in experimental animals or prevent reactivation of previous infection, when administered as a vaccine.
  • the composition used for therapeutic vaccines can be prepared as described above for vaccines.
  • the invention also relates to a method of diagnosing TB caused by a virulent mycobacterium in an animal, including a human being, comprising intradermally injecting, in the animal, a polypeptide according to the invention, a positive skin response at the location of injection being indicative of the animal having TB, and a negative skin response at the lo- cation of injection being indicative of the animal not having TB.
  • a blood sample comprising mononuclear cells (i.e. T-lymphocytes) from a patient could be contacted with a sample of one or more polypeptides of the invention. This contacting can be performed in vitro and a positive reaction could e.g.
  • the invention therefore also relates to an in vitro method for diagnosing ongoing or previous sensitisation in an animal or a human being with a virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and contacting the sample from the animal with the polypeptide of the invention, a significant re- lease into the extracellular phase of at least one cytokine by mononuclear cells in the blood sample being indicative of the animal being sensitised.
  • a positive response being a response more than release from a blood sample derived from a patient without the TB diagnosis plus two standard derivations.
  • the invention also relates to the in vitro method for diagnosing ongoing or previous sensitisation in an animal or a human being with a virulent mycobacterium, the method comprising providing a blood sample from the animal or human being, and by contacting the sample from the animal with the polypeptide of the invention demonstrating the presence of antibodies recognizing the polypeptide of the invention in the serum sample.
  • the immunogenic composition used for diagnosing may comprise 1-20, such as 2-20 or even 3-20 different polypeptides or fusion polypeptides, such as 3-10 different polypeptides or fusion polypeptides.
  • the nucleic acid probes encoding the polypeptide of the invention can be used in a variety of diagnostic assays for detecting the presence of pathogenic organisms in a given sample.
  • Such a method of diagnosing TB might involve the use of a composition comprising at least a part of a nucleotide sequence as defined above and detecting the presence of nucleotide sequences in a sample from the animal or human being to be tested which hybridise with the nucleic acid fragment (or a complementary fragment) by the use of PCR technique.
  • a monoclonal or polyclonal antibody which is specifically reacting with a polypeptide of the invention in an immuno assay, or a specific binding fragment of said antibody, is also a part of the invention.
  • the antibodies can be produced by methods known to the person skilled in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of a polypeptide according to the present invention and, if desired, an adjuvant.
  • the monoclonal antibodies according to the present invention may, for example, be produced by the hybridoma method first described by Kohler and Milstein (1975), or may be produced by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567.
  • the monoclonal antibodies may also be isolated from phage libraries generated using the techniques described by McCafferty et al (1990), for example. Methods for producing antibodies are described in the literature, e.g. in US 6,136,958.
  • a sample of a potentially infected organ may be contacted with such an antibody recog- nizing a polypeptide of the invention.
  • the demonstration of the reaction by means of methods well known in the art between the sample and the antibody will be indicative of an ongoing infection. It is of course also a possibility to demonstrate the presence of anti- mycobacterial antibodies in serum by contacting a serum sample from a subject with at least one of the polypeptide fragments of the invention and using well-known methods for visualising the reaction between the antibody and antigen.
  • an antibody, a nucleic acid fragment and/or a polypeptide of the invention can be used either alone, or as a constituent in a composition.
  • Such compositions are known in the art, and comprise compositions in which the antibody, the nucleic acid frag- ment or the polypeptide of the invention is coupled, preferably covalently, to at least one other molecule, e.g. a label (e.g. radioactive or fluorescent) or a carrier molecule.
  • Figure 1 Stimulation of IFN- ⁇ production by synthetic peptides in PBMC from PPD positive healthy donors. Single peptides were tested at concentrations of 10 ⁇ g, 5 ⁇ g and 2.5 ⁇ g/ml in 200 ⁇ l of cell culture. Pools of peptides were tested at 1 ⁇ g, 0.5 ⁇ g and 0.25 ⁇ g/ml of each peptide. Results are presented as pg IFN- ⁇ /ml of the maximum stimulation. Recombinant antigens were included for comparison.
  • Figure 2A The antibody response of 48 TB patients to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1ug/ml ORF13A and the serum is di- luted 1 :100 in PBS.
  • Figure 2B The antibody response of 15 BCG vaccinated healthy donors to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1 ⁇ g/ml ORF13A and the serum is diluted 1 :100 in PBS.
  • Figure 2C The antibody response of 19 non BCG-vaccinated healthy donors to ORF13A evaluated by ELISA. The OD indicated is the mean of two wells coated with 1 ⁇ g/ml ORF13A and the serum is diluted 1 :100 in PBS.
  • FIG. 3 Stimulation of T-cell proliferation by synthetic peptides derived from Rv3878.
  • the coding region of Rv0285, Rv3878, the 3 ' -part (380 bp) of Rv0284 and 5 ' -part of ORF13A (543 bp of Rv3879c) were amplified by PCR using following primer sets:
  • Rv0284-F CTG AGA TCT CAG GTA CCG GAT TCG CCG
  • Rv0284-R CTC CCA TGG TCA TGA CTG ACT CCC CTT Ncol
  • Rv0285-F CTG AGA TCT ATG ACG TTG CGA GTG GTT
  • Rv0285-R CTC CCA TGG TCA GCC GCC CAC GAC CCC
  • Rv3878-F CTG AGA TCT GCT ACT GTT AAC AGA TCG
  • Rv3878-R CCG CTC GAG CTA CAA CGT TGT GGT TGT Xhol
  • ORF13A-F CCC AAG CTT ATG AGT ATT ACC AGG CCG HindiII
  • ORF13A-R CTC CCA TGG TCA CGA CTT CTG CTG AAG CAA
  • PCR reactions contained 10 ng of M. tuberculosis H37Rv DNA in 1x low salt Taq + buffer from Stratagene supplemented with 250 ⁇ M of each of the four nucleotides (Boehringer
  • the PCR fragments were cloned into the TA cloning vector pCR2.1 (Invitrogen) and then transferred to the pMCT3 expression vector at the restriction sites indicated by the prim- ers above.
  • the coding regions of Rv1195, Rv1386 and Rv3477 were amplified by PCR using the following primer sets:
  • Rvll95-F gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgTCTTTCgTgATggCATACC
  • Rvll95-R gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA TTAgCTggCCgCCgC
  • Rvl386-F gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgACgTTgCgAgTCgTTCC
  • Rvl386-R gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA TAgCCCACCgCTgAgATACg
  • Rv3477-F gggg ACA AgT TTg TAc AAA AAA gCA ggC TTA gTgTCTTTCACTgCgCAACCg
  • Rv3477-R gggg AC CAC TTT gTA CAA gAA AgC Tgg gTC CTA gCCggTgACCACAgCgTT PCR reactions were carried out by Platinum ® Tag DNA Polymerase (GIBCOBRL ® ) in 50 ⁇ l reaction volume containing 60 mM Tris-SO 4 (pH 8.9), 18 mM Ammonium Sulfate, 0.2 mM of each of the four nucleotides, 0.2 ⁇ M of each primer and 10 ng of M. tuberculosis H37Rv DNA.
  • GIBCOBRL ® Platinum ® Tag DNA Polymerase
  • the reaction mixtures were initially heated to 95°C for 5 min, followed by 35 cycles of 95°C for 45 sec, 60°C for 45 sec and 72°C for 2 min, and finally by 72°C for 15 min.
  • the PCR products were precipitated by PEG/MgCI 2 , and then dissolved in 50 ⁇ l of TE buffer.
  • DNA fragments were then cloned and expressed in GatewayTM Cloning system (GIBCOBRL ® ).
  • GIBCOBRL ® GatewayTM Cloning system
  • the cell pellet was resuspended in 20 ml of Sonication buffer (20 mM Tris- Cl, pH 8.0, 0.5 M NaCl, 10% Glycerol, 5 mM ⁇ -ME, 0.01% Tween 20 and 1 mM imida- zole).
  • Cells were lysed and DNA was digested by treating with lysozyme (0.1 mg/ml) and DNase I (2.5 ⁇ g/ml) at room temperature for 20 min with gentle agitation.
  • the recombinant protein was bring to solution by adding 80 ml of Sonication Buffer containing 8 M urea and sonicated the sample 5 x 30 sec, with 30 sec pausing between the pulses.
  • the lysate was applied to a 5 ml TALON column (Clonetech). The column was then washed with 25 ml of urea containing Sonication buffer, and the bound protein was eluted by imidazole steps (5, 10, 20, 40 and 100 mM) in the same buffer. The fractions were analyzed by silver stained SDS-PAGE, and recombinant protein containing fractions were pooled.
  • Example 2 Biological activity of the recombinant antigens.
  • the purified recombinant proteins were screened for the ability to induce a T cell re- sponse measured as IFN- ⁇ release and/or cell proliferation.
  • a preliminary screening involved testing of the IFN- ⁇ induction and/or cell proliferation of T cell lines generated from PPD positive donors. This test was followed by measuring the response in PBMC preparations obtained from TB patients, PPD positive as well as negative healthy donors.
  • PBMC Human donors: PBMC were obtained from healthy donors with a positive in vitro response to PPD.
  • T cell line preparation T cell lines were prepared by culturing 5 x 10 6 freshly isolated PBMC/ml with viable M. tuberculosis at a ratio of 5 bacteria per macrophage in a total vol- ume of 1 ml. The cells were cultured in RPMI 1640 medium (Gibco, Grand Island, N.Y) supplemented with HEPES, and 10% heat-inactivated NHS. After 7 days in culture at 37°C and 5% CO 2 , T cells were supplemented with 50 U/ml of r-IL-2 (Boehringer Mannheim) for approximately 7 days.
  • T cell lines were tested for reactivity against the recombinant antigens by stimulating 1-5 x 10 5 cells/ml with 5 ⁇ g/ml of PPD, 3 ⁇ g/ml of rRv0284ct (C-terminal part), 5 ⁇ g/ml of rRv0285, and 2.5 ⁇ g/ml of rRv3878 in the presence of 5 x 10 5 autologous antigen-presenting cells/ml.
  • Table 1a T cells were stimulated with 5 ug/ml and 1 ⁇ g/ml of each recombi- nant antigen indicated in the table. No ag and PHA were used as negative and positive controls, respectively. The supematants were harvested after 4 days of culture and stored at -80°C until the presence of IFN- ⁇ were analysed.
  • IFN- ⁇ Interferon- ⁇
  • MA, US monoclonal antibodies
  • Recombinant IFN- ⁇ was used as a standard. All data are means of duplicate wells and the variation between the wells did not exceed 10 % of the mean. Responses obtained with five T cell lines are shown in Table 1 and Table 1a.
  • T-cell proliferation assays After removal of supernatant for IFN- ⁇ assays, 0.5 ⁇ Ci of [methyl-3H]thymidine were added to the same wells supplemented with 10% NHS in RPMI for another 16-20 hours. The cells were thereafter harvested with a Skatron cell harvester onto filter mats, dried, and immersed in scintillation fluid before reading the in- corporation of thymidine on a beta liquid scintillation counter (Wallac). Results from 3 T cell lines are shown in Table 1 b.
  • T cell line 50 1482 803 352 548 667 Table 1a. Stimulation of three T cell lines with rRv0285 and rRv3878. Responses to PHA and PPD are shown for comparison. Results are presented as pg IFN- ⁇ /ml of the maximum stimulation in the presence of either 5 ⁇ g/ml or 1 ⁇ g/ml of recombinant antigens.
  • Table 1 b Stimulation of T cell proliferation by rRv0285 and rRv3878. Results are presented as Stimulation Index (SI). The maximum stimulation in the presence of either 5
  • PBMC Human donors: PBMC were obtained from healthy donors with a positive in vitro response to purified protein derivative (PPD) or non-vaccinated healthy donors with a nega- tive in vitro response to PPD. PBMC were also obtained from TB patients with microscopy or culture proven infection. Blood samples were drawn from TB patients 0-6 months after diagnosis.
  • PPD purified protein derivative
  • Lymphocyte preparations and cell culture PBMC were freshly isolated by gradient centrifugation of heparinized blood on Lymphoprep (Nycomed, Oslo, Norway) and stored in liquid nitrogen until use. The cells were resuspended in complete RPMI 1640 medium (Gibco BRL, Life Technologies) supplemented with 1% penicillin/streptomycin (Gibco BRL, Life Technologies), 1% non-essential-amino acids (FLOW, ICN Biomedicals, CA, USA), and 10% heat-inactivated normal human AB serum (NHS). The viability and num- ber of the cells were determined by Nigrosin staining.
  • the skin test reactivity of the recombinant antigens was tested in M. tuberculosis infected guinea pigs.
  • a group of 5 female outbred guinea pigs of the Dunkin Hartley strains (M ⁇ l- legaard Breeding and Research Center A/S, Lille Skensved, Denmark) were infected by the aerosol route in an exposure chamber of a Glas-Col® Inhalation Exposure System, which was calibrated to deliver approximately 20-25 M. tuberculosis Erdman bacilli into the lungs of each animal.
  • a Glas-Col® Inhalation Exposure System which was calibrated to deliver approximately 20-25 M. tuberculosis Erdman bacilli into the lungs of each animal.
  • the skin test reactivity of uninfected guinea pigs was tested.
  • Skin tests were performed 28 days after infection with injection of 5 ⁇ g of rRv0284ct, rRv0285, and rRv3878.
  • Skin test responses (diameter of erythema) were read 24 h later by two experienced examinators and the results were expressed as the mean of the two readings. The variation between the two readings was less than 10%. Skin test responses larger than 5 mm were regarded as positive.
  • Peptide synthesis Ten overlapping peptides to Rv0285 and Rv1386 respectively, were synthesized. Synthetic polypeptides were purchased from Mimotopes Pty Ltd. The peptides were synthesized by Fmoc solid phase strategy. No purification steps were performed. Lyophilised peptides were stored dry until use.
  • PBMC culture and IFN- ⁇ assay PBMC were isolated and cultured as described in Example 2. Single peptides were tested at concentrations of 10 ⁇ g, 5 ⁇ g and 2.5 ⁇ g/ml in 200 ⁇ l of cell culture. Pools of peptides were tested at 1 ⁇ g, 0.5 ⁇ g and 0.25 ⁇ g/ml of each peptide. IFN- ⁇ levels were measured by the method described in Example 2.
  • the ability of these peptides to induce IFN- ⁇ production in PBMC was assayed.
  • the results from three PPD positive healthy donors (referred to as KTB1 , KTB10 and K172, respectively) are shown in Fig.1.
  • the pools of peptides from Rv0285 (referred to as Rv0285 p1 - Rv0285 p10) stimulated IFN- ⁇ production in PBMC from all three donors. This is consistent with the results obtained with recombinant Rv0285 (Table 2a and Fig.1).
  • seven peptides were recognized by the three donors, indicating the presence of multiple immunogenic portions scattered through out the protein sequence of Rv0285.
  • the pools of peptides from Rv1386 and recombinant Rv1386 stimulated IFN- ⁇ production in PBMC from two of the three donors. Four of the peptides were also positive when tested as single peptides. The synthetic peptides were also tested in PBMC from two PPD negative controls; as expected, no stimulation of IFN- ⁇ production was detected for these donors (results not shown).
  • Example 3a PBMC recognition of peptides derived from MT3106.1
  • a BLAST-P search of the GMT.pep database at TIGR CMR revealed an open reading frame which is highly related to Rv0285.
  • This ORF is designated MT3106.1
  • the pre- dieted initiation codon is 33 codons upstream of the corresponding initiation codon in Rv0285.
  • Amino acid sequence alignment revealed that the Rv0285-corresponding part of MT3106.1 has 80% sequence identity to the former, and a peptide fragment spanning residues 2 -29 on Rv0285 is 100% conserved on Mt.3106.1.
  • This segment of peptide contains at least 2 distinct T-cell epitopes as demonstrated by the results in Fig. 1 (Rv0285-p1 and Rv0285-p2, respectively).
  • MT3106.1-p1 - MT3106.1-p11 Eleven additional overlapping peptides of MT3106.1 (MT3106.1-p1 - MT3106.1-p11 , SEQ ID NO 146-156) were synthesized and analyzed for their ability to induce IFN- ⁇ production in PBMCs from donor K172.
  • Peptide MT3106.1-p7 was highly reactive and stimulated IFN- ⁇ production to a level of 12079 pg/ml, which corresponds to 87% of the activity obtained with PPD.
  • Example 3b Recognition of synthetic peptides by T-cell lines derived from PBMC of PPD positive subjects.
  • Non-overlapping peptides (Rv0284-p1 - Rv0284-p69, SEQ ID NO 54-122) were synthesized for the part of Rv0284 that was not included in rRv0284ct. Peptides were tested as pools consisting of 2 or 3 peptides each. T-cell stimulatory effects were seen in a number of peptide pools.
  • ST-CF Short-time culture filtrate
  • the culture filtrate was hereafter precipitation with 80 % ammonium sulphate and the precipitated proteins were removed by centrifugation and after washing resuspended in buffer containing 5 8 M urea, CHAPS 0.5% (w/v) and 5% glycerol.
  • 250 mg of protein was separated on the Rotofor Isoelectrical Cell (Bio-Rad) in a pH gradient with 3% Biolyt 3/5 and 1% Biolyt 4/6.
  • Fraction 3-8 were pooled, concentrated and buffer exchanged to PBS on a Centriprep concentrator with a 3 kDa cut off membrane.
  • the two spots were named TB9.5 and TB13.7.
  • TB9.5 MKAKVGDILVIKGAT (SEQ ID NO 171)
  • TB13.7 DSTEDFPIPXRMXAT (SEQ ID NO 172)
  • X denotes an amino acid, which could not be determined.
  • the two sequences were used for a homology search using the BLAST program on the 25 M. tuberculosis database: http://genolist.pasteur.fr/TubercuList/.
  • the 15 determined amino acids was 100% identical to the sequence of Rv0569, which is an 88 amino acids long protein.
  • the 13 determined amino acids was 100% identical to the sequence of Rv0455c.
  • the 13 N-terminally determined amino acids starts at amino acids 31 in the predicted sequence of Rv0455c, indication the presence of a signal peptide, 30 which has been cleaved off.
  • TB9.5-1 MKAKVGDWLVIKGATIDQPDHRGLIIEVRS TB9.5-2: HRGLIIEVRSSDGSPPYWRWLETDHVATV TB9.5-3: VRWLETDHVATVIPGPDAVWTAEEQNAAD TB9.5-4: VTAEEQNAADERAQHRFGAVQSAILHARGT
  • TB13.7-1 DSTEDFPIPRRMIATTCDAEQYLAAVRDTS TB13.7-2: QYLAAVRDTSPVYYQRYMIDFNNHANLQQA TB13.7-3: FNNHANLQQATINKAHWFFSLSPAERRDYS TB13.7-4: LSPAERRDYSEHFYNGDPLTFAWVNHMKIF TB13.7-5: FAWVNHMKIFFNNKGWAKGTEVCNGY
  • the immunological relevance of the peptides in TB patients was tested by analysing the ability of the peptides to induce an IFN- ⁇ production or a cell proliferation on PBMC isolated from human TB patients and PPD negative healthy controls (table 5 and table 7).
  • the TB9.5 peptides were in addition tested for ability to induce IFN- ⁇ and cell proliferation on T cell lines generated from TB patients driven by ST-CF or M. tuberculosis sonicate (table 6). Lymphocyte preparation and T-cell lines generation were performed as de- scribed in example 2.
  • Table 5 Stimulation of PBMC from three TB patients and three PPD negative healthy controls with pools of synthetic peptides from TB9.5 and TB.13.7 in total of 10 ug/ml.
  • 2.5 ug/ml of each peptide TB9.5-1 , TB9.5-2, TB9.5-3 and TB9.5-4 were pooled and tested as TB9.5.
  • 2 ug/ml of each peptide TB13.7-1 , TB13.7-2, TB13.7-3, TB13.7-4 and TB13.7-5 were pooled and tested as TB13.7.
  • the response to 5 ug/ml ST-CF is shown for comparison. Results are presented as pg IFN- ⁇ /ml.
  • TB9.5-1 was posi- tive in most of the tested T-cell lines demonstrating the presence of one or more broadly recognized T cell epitope within this sequence (table 6).
  • TB9.5-2, TB9.5-3 and T9.5-4 were positive in at least one out of the five T cell lines tested demonstrating that these sequences also contains at least one T cell epitope.
  • the presence of multiple epitopes in the TB9.5 protein makes the full-length protein or peptides derived hereof an attractive candidate for a TB vaccine.
  • Tabel 6 Stimulation of five T cell lines derived from TB patients with synthetic overlapping peptides from TB9.5. Results are presented as pg IFN- ⁇ /ml and cell proliferation. The peptides are tested in 1 ug/ml and 10ug/ml and results are shown for the concentration given the highest response. The response to 5 ug/ml ST-CF is shown for comparison.
  • Table 7 Stimulation of PBMCs from two TB patients and two healthy controls with synthetic peptides from the TB13.7 protein. Responses to PPD are given for comparison. Control is stimulation without antigen. Results are given as pg IFN- ⁇ /ml
  • the 13.7 peptides were tested on PBMC isolated from two TB patients and two healthy controls. As seen in table 7 one of the two TB patients recognized peptide TB13.7-5 while no of the healthy controls recognized any of the peptides tested. This demonstrates that an epitope is presence in peptide TB13.7-5, but does not rule out the presence of epitopes in any of the other peptides. To demonstrate this it would be necessary to test a higher number of TB patients due to the genetically heterogeneity of the human popula- tion.
  • Immunogenic proteins may be identified by the means of their upregulation in vivo or in environments which reflects the in vivo situation. This may be different stress situations such as low oxygen.
  • M. tuberculosis H37Rv ATCC 27240 was cultured in Sauton medium enriched with 0.5 % sodium pyruvate and 0.5 % glucose.
  • the gel was blotted to PVDF membrane, and the membrane was exposed to Biomax MR film (Kodak, Rochester, NY, USA) for 3-21 days.
  • the autoradiographs were scanned and analysed by the Phoretix 2D gel analysis software (Non Linear Dynamics, Newcastle upon Tyne, United Kingdom). Spots which showed more than two-fold induction under low oxygen conditions compared to normal cultures were selected. A spot with observed mass of approx. 12 kDa and pi of 6.3 was found to be induced under low oxygen conditions. For identification of this spot, 35 ⁇ l of the low oxygen lysate was analysed by 2-D PAGE as described above and the gel was silver stained. The relevant spot was excised and identified by MALDI-MS peptide mass fingerprinting.
  • ORF13A is a serological target in TB patients
  • ORF13A As a serological antigen, sera were collected from 48 TB patients (all proven culture positive for M. tuberculosis) and 15 healthy BCG vaccinated controls and 19 non-BCG vaccinated healthy controls. The sera were assayed for anti- bodies recognizing the recombinantly produced ORF13A in an ELISA assay as follows: Each of the sera was absorbed with Promega E. coli extract (S37761) for 4 hours at room temperature and the supernatants collected after centrifugation. 1 ug/ml of ORF13A in Carbonatbuffer pH 9.6 were absorbed over night at 5 °C to a polystyrene plate (Maxisorp, Nunc).
  • the plates were washed in PBS-0.05% Tween-20 and the sera applied in a dilu- tion of 1 :100. After 1 hour of incubation the plates were washed 3 times with PBS-0.05% Tween-20 and 100 ul per well of peroxidase-conjugated Rabbit Anti-Human IgA, IgG, IgM was applied in a dilution of 1 :8000. After 1 hour of incubation the plates were washed 3 times with PBS-0.05% Tween-20. 100 ul of substrate (TMB PLUS, Kem-En-Tec) was added per well and the reaction stopped after 30 min with 0.2 M Sulphuric acid and the absorbance was read at 405 nm. The results are shown in figure 2A, 2B and 2C.
  • ORF13A As a serological antigen for the diagnosis of TB, and demonstrates that ORF13A has the potential to differentiate between BCG vaccinated and M. tuberculosis infected individuals something, which is not possible with the current diagnostic reagent PPD. It is well known that the antibody repertoire of TB patients is very heterogeneous and it is therefore not likely that all patients will recognized the same mycobacterial antigen, as also demonstrated by these results. It is therefore most likely that a serological kit for the diagnosis of M. tuberculosis infection will consist of more than one component and in this respect it will be obvious to combine ORF13A with other antigens, which are recognized by TB patients. This could be the 38 kDa antigens, but also other proteins could be included.
  • Patent application US 09/0505,739 "Nucleic acid fragments and polypeptide fragments 25 derived from M. tuberculosis"

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'identification et la caractérisation de plusieurs nouvelles protéines et nouveaux fragments de protéines dérivées de ∫i⊃M. tuberculosis∫/i⊃. L'invention se rapporte aux polypeptides et aux fragments immunologiquement actifs de ceux-ci, aux gènes les codant, à des compositions immunologiques telles que des vaccins et à des réactifs pour tests cutanés contenant les polypeptides de l'invention.
EP01923542A 2000-04-19 2001-04-19 Antigenes de la tuberculose et procedes de leur utilisation Withdrawn EP1278769A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000666 2000-04-19
DK200000666 2000-04-19
DK200100283 2001-02-21
DKPA200100283 2001-02-21
PCT/DK2001/000276 WO2001079274A2 (fr) 2000-04-19 2001-04-19 Antigenes de la tuberculose

Publications (1)

Publication Number Publication Date
EP1278769A2 true EP1278769A2 (fr) 2003-01-29

Family

ID=26068815

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01923542A Withdrawn EP1278769A2 (fr) 2000-04-19 2001-04-19 Antigenes de la tuberculose et procedes de leur utilisation

Country Status (4)

Country Link
EP (1) EP1278769A2 (fr)
AU (1) AU2001250294A1 (fr)
CA (1) CA2405247A1 (fr)
WO (1) WO2001079274A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE429245T1 (de) 1999-05-04 2009-05-15 Univ New Jersey Med Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe
AU2003242504A1 (en) 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
DE10251747A1 (de) * 2002-11-05 2004-05-19 Tuhh-Technologie-Gmbh Gentechnisch veränderte Penicillinamidase und Verfahren zu ihrer Herstellung
WO2004099771A1 (fr) 2003-05-08 2004-11-18 Statens Serum Institut Methode de diagnostic immunologique de la tuberculose basee sur de nouveaux epitopes specifiques
WO2005061534A2 (fr) * 2003-12-23 2005-07-07 Statens Serum Institut Vaccins antituberculeux ameliores
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
GB0406271D0 (en) 2004-03-19 2004-04-21 Isis Innovation Diagnostic test
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
CA2612900C (fr) 2005-06-23 2016-08-09 Claus Aagaard Vaccins ameliores contre la tuberculose
EP2889041A1 (fr) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit de réactifs pour dosage de la tuberculose
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2714383T3 (es) 2009-04-24 2019-05-28 Statens Seruminstitut Vacuna TB contra la tuberculosis para impedir la reactivación
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011063283A2 (fr) 2009-11-20 2011-05-26 Oregon Health & Science University Procédés destinés à détecter une infection par mycobacterium tuberculosis
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
WO2018111536A1 (fr) 2016-12-14 2018-06-21 Becton, Dickinson And Company Procédés et compositions permettant d'obtenir une évaluation de la tuberculose chez un sujet
CN111551741B (zh) * 2016-12-30 2023-06-16 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途
GB2621127A (en) * 2022-07-29 2024-02-07 Univ Johannesburg Witwatersrand Vaccine constructs comprising tuberculosis antigens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2285625C (fr) * 1997-04-02 2015-06-30 Statens Serum Institut Fragments d'acide nucleique et fragments polypeptidiques derives de m. tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
CA2319380A1 (fr) * 1997-11-10 1999-05-20 Statens Serum Institut Fragments d'acides nucleiques et fragments polypeptidiques derives de m. tuberculosis
WO2000066143A1 (fr) * 1999-05-04 2000-11-09 The Public Health Research Institute Of The City Of New York, Inc. Proteines secretees par mycobacterium tuberculosis et utilisations comme vaccins et reactifs de diagnostic
ATE429245T1 (de) * 1999-05-04 2009-05-15 Univ New Jersey Med Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0179274A2 *

Also Published As

Publication number Publication date
WO2001079274A8 (fr) 2004-04-29
CA2405247A1 (fr) 2001-10-25
WO2001079274B1 (fr) 2002-08-08
WO2001079274A3 (fr) 2002-07-11
AU2001250294A1 (en) 2001-10-30
WO2001079274A2 (fr) 2001-10-25

Similar Documents

Publication Publication Date Title
EP1523331B1 (fr) Vaccin therapeutique contre la tuberculose
US7037510B2 (en) Hybrids of M. tuberculosis antigens
WO2001079274A2 (fr) Antigenes de la tuberculose
US10519202B2 (en) Tuberculosis TB vaccine to prevent reactivation
AU723606B2 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
JP4162155B2 (ja) 結核の免疫治療および診断のための化合物およびそれらの使用方法
AU779495B2 (en) Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family
US5985287A (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
JP2003510018A5 (fr)
WO2005061534A2 (fr) Vaccins antituberculeux ameliores
US20040013685A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
AU2012202486B2 (en) Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family
AU741016B2 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855A1 (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030113

17Q First examination report despatched

Effective date: 20040715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051101